Current status and prospects for development of an HSV vaccine

Vaccine

Volumn 32, Issue 14, 2014, Pages 1553-1560

  Johnston, Christine ^a,b   Koelle, David M ^a,b,c   Wald, Anna ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Genital herpes; Herpes simplex virus; Vaccine

Indexed keywords

GLYCOPROTEIN D; GLYCOPROTEIN D2; HERPES SIMPLEX VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ARTICLE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VACCINATION; VIRUS PATHOGENESIS; VIRUS REACTIVATION;

GENITAL HERPES; HERPES SIMPLEX VIRUS; VACCINE;

ANIMALS; EPITOPES, T-LYMPHOCYTE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNITY, MUCOSAL; VACCINATION; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS;

EID: 84896706485     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.066     Document Type: Article

References (115)

1. Looker K.J., Garnett G.P., Schmid G.P. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008, 86:805A-812A.
2. Owusu-Edusei K.J., Chesson H.W., Gift T.L., Tao G., Mahajan R., Ocfemia M.C.B., et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013, 40:197-201. 10.1097/OLQ.0b013e318285c6d2.
3. Center for Disease Control and Prevention Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years - United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2010, 59:456-459.
4. Paz-Bailey G., Ramaswamy M., Hawkes S.J., Geretti A.M. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect 2007, 83:16-22.
5. Watson-Jones D., Weiss H.A., Rusizoka M., Baisley K., Mugeye K., Changalucha J., et al. Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: preparing for an HSV-2 intervention trial. J Acquir Immune Defic Syndr 2007, 46:631-642.
6. Xu F., Sternberg M.R., Kottiri B.J., McQuillan G.M., Lee F.K., Nahmias A.J., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296:964-973.
7. Mertz K.J., Trees D., Levine W.C., Lewis J.S., Litchfield B., Pettus K.S., et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998, 178:1795-1798.
8. Paz-Bailey G., Rahman M., Chen C., Ballard R., Moffat H.J., Kenyon T., et al. Changes in the etiology of sexually transmitted diseases in Botswana between 1993 and 2002: implications for the clinical management of genital ulcer disease. Clin Infect Dis 2005, 41:1304-1312.
9. Xu F., Schillinger J.A., Sternberg M.R., Johnson R.E., Lee F.K., Nahmias A.J., et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis 2002, 185:1019-1024.
10. Mertz G.J., Benedetti J., Ashley R., Selke S.A., Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992, 116:197-202.
11. Langenberg A.G., Corey L., Ashley R.L., Leong W.P., Straus S.E. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999, 341:1432-1438.
12. Kimberlin D.W., Lin C.-Y., Jacobs R.F., Powell D.A., Frenkel L.M., Gruber W.C., et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001, 108:223-229.
13. Brown Z.A., Selke S., Zeh J., Kopelman J., Maslow A., Ashley R.L., et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997, 337:509-515.
14. Dinh T.-H., Dunne E.F., Markowitz L.E., Weinstock H., Berman S. Assessing neonatal herpes reporting in the United States, 2000-2005. Sex Transm Dis 2008, 35:19-21. 10.1097/OLQ.0b013e318162c4c6.
15. Brown Z.A., Wald A., Morrow R.A., Selke S., Zeh J., Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003, 289:203-209.
16. Freeman E.E., Weiss H.A., Glynn J.R., Cross P.L., Whitworth J.A., Hayes R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20:73-83.
17. Reynolds S.J., Risbud A.R., Shepherd M.E., Zenilman J.M., Brookmeyer R.S., Paranjape R.S., et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003, 187:1513-1521. [see comment].
18. Tobian A., Charvat B., Ssempijja V., Kigozi G., Serwadda D., Makumbi F., et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infection among men in Rakai, Uganda. J Infect Dis 2009, 199:945-949.
19. Schacker T., Ryncarz A.J., Goddard J., Diem K., Shaughnessy M., Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998, 280:61-66.
20. Gray R.H., Wawer M.J., Brookmeyer R., Sewankambo N.K., Serwadda D., Wabwire-Mangen F., et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual. HIV-1-discordant couples in Rakai, Uganda. Lancet 2001, 357:1149-1153.
21. Wald A., Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002, 185:45-52.
22. Freeman E.E., White R.G., Bakker R., Orroth K.K., Weiss H.A., Buvé A., et al. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine 2009, 27:940-946.
23. Zhu J., Hladik F., Woodward A., Klock A., Peng T., Johnston C., et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nature Med 2009, 15:886-U83.
24. Johnson K., Sherman M., Ssempiija V., Tobian A., Zenilman J., Duggan M., et al. Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda. AIDS 2009, 23:1807-1815.
25. Rebbapragada A., Wachihi C., Pettengell C., Sunderji S., Huibner S., Jaoko W., et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007, 21:589-598.
26. Corey L., Wald A., Patel R., Sacks S.L., Tyring S.K., Warren T., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004, 350:11-20.
27. Wald A., Krantz E., Selke S., Lairson E., Morrow R.A., Zeh J. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006, 194:42-52.
28. Martin E.T., Krantz E., Gottlieb S.L., Magaret A.S., Langenberg A., Stanberry L., et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009, 169:1233-1240.
29. Tobian A.A.R., Serwadda D., Quinn T.C., Kigozi G., Gravitt P.E., Laeyendecker O., et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009, 360:1298-1309.
30. Tobian A.A.R., Kigozi G., Redd A.D., Serwadda D., Kong X., Oliver A., et al. Male circumcision and herpes simplex virus type 2 infection in female partners: a randomized trial in Rakai, Uganda. J Infect Dis 2012, 205:486-490.
31. Mujugira A., Magaret A.S., Celum C., Baeten J.M., Lingappa J.R., Morrow R.A., et al. Daily acyclovir to decrease HSV-2 transmission from HSV-2/HIV-1 co-infected persons: a randomized controlled trial. J Infect Dis 2013, [Epub ahead of print].
32. Ryder N., Jin F., McNulty A.M., Grulich A.E., Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006. Sex Transm Infect 2009, 85:416-419.
33. Looker K.J., Garnett G.P. A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect 2005, 81:103-107.
34. Cunningham A.L., Diefenbach R.J., Miranda-Saksena M., Bosnjak L., Kim M., Jones C., et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J Infect Dis 2006, 194(Suppl. 1):S11-S18.
35. Oxman M.N. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010, 51:197-213.
36. Mark K.E., Wald A., Magaret A.S., Selke S., Kuntz S., Huang M.L., et al. Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. J Acquir Immune Defic Syndr 2010, 54:482-488.
37. Mark K.E., Wald A., Magaret A.S., Selke S., Olin L., Huang M.L., et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008, 198:1141-1149.
38. Schiffer J.T., Abu-Raddad L., Mark K.E., Zhu J., Selke S., Koelle D.M., et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A 2010, 107:18973-18978.
39. Shin H., Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012, 491:463-467.
40. Stanberry L.R., Kern E.R., Richards J.T., Abbott T.M., Overall J.C. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis 1982, 146:397-404.
41. Yim K.C., Carroll C.J., Tuyama A., Cheshenko N., Carlucci M.J., Porter D.D., et al. The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol 2005, 79:14632-14639.
42. Crostarosa F., Aravantinou M., Akpogheneta O.J., Jasny E., Shaw A., Kenney J., et al. A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS ONE 2009, 4:e8060.
43. Herman M., Ciancanelli M., Ou Y.-H., Lorenzo L., Klaudel-Dreszler M., Pauwels E., et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp Med 2012, 209:1567-1582.
44. Davey G.M., Wojtasiak M., Proietto A.I., Carbone F.R., Heath W.R., Bedoui S., et al. Priming of CD8 T cell immunity to herpes simplex virus type 1 requires cognate TLR3 expression in vivo. J Immunol 2010, 184:2243-2246.
45. ®-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes. Vaccine 2012, 30:4361-4368.
46. Svensson A., Tunbäck P., Nordström I., Padyukov L., Eriksson K. Polymorphisms in Toll-like receptor 3 confer natural resistance to human herpes simplex virus type 2 infection. J Gen Virol 2012, 93:1717-1724.
47. Bochud P.Y., Magaret A.S., Koelle D.M., Aderem A., Wald A. Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection. J Infect Dis 2007, 196:505-509.
48. Yang C.-A., Raftery M.J., Hamann L., Guerreiro M., Grütz G., Haase D., et al. Association of TLR3-hyporesponsiveness and functional TLR3 L412F polymorphism with recurrent herpes labialis. Hum Immunol 2012, 73:844-851.
49. Moraru M., Cisneros E., Gómez-Lozano N., de Pablo R., Portero F., Cañizares M., et al. Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity. J Immunol 2012, 188:4412-4420.
50. Balachandran N., Bacchetti S., Rawls W.E. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun 1982, 37:1132-1137.
51. Schiller J.T., Castellsagué X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Supplement 5):F123-F38.
52. Kopp S.J., Karaba A.H., Cohen L.K., Banisadr G., Miller R.J., Muller W.J. Pathogenesis of neonatal herpes simplex 2 disease in a mouse model is dependent on entry receptor expression and route of inoculation. J Virol 2013, 87:474-481.
53. Wang K., Kappel J.D., Canders C., Davila W.F., Sayre D., Chavez M., et al. A herpes simplex virus 2 glycoprotein D mutant generated by bacterial artificial chromosome mutagenesis is severely impaired for infecting neuronal cells and infects only vero cells expressing exogenous HVEM. J Virol 2012, 86:12891-12902.
54. Eisenberg R.J., Atanasiu D., Cairns T.M., Gallagher J.R., Krummenacher C., Cohen G.H. Herpes virus fusion and entry: a story with many characters. Viruses 2012, 4:800-832.
55. Taylor J.M., Lin E., Susmarski N., Yoon M., Zago A., Ware C.F., et al. Alternative entry receptors for herpes simplex virus and their roles in disease. Cell Host Microbe 2007, 2:19-28.
56. Liao H.-X., Bonsignori M., Alam S.M., McLellan Jason S., Tomaras Georgia D., Moody M.A., et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013, 38:176-186.
57. Krause J.C., Tsibane T., Tumpey T.M., Huffman C.J., Albrecht R., Blum D.L., et al. Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol 2012, 86:6334-6340.
58. Zhu J., Koelle D.M., Cao J., Vazquez J., Huang M.L., Hladik F., et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007, 204:595-603.
59. Peng T., Zhu J., Phasouk K., Koelle D.M., Wald A., Corey L. An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of HSV-2 infection. J Virol 2012, 86:10587-10596.
60. Mackay L.K., Stock A.T., Ma J.Z., Jones C.M., Kent S.J., Mueller S.N., et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci 2012, 109:7037-7042.
61. Moss N.J., Magaret A., Laing K.J., Kask A.S., Wang M., Mark K.E., et al. Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes. J Virol 2012, 86:9952-9963.
62. Jing L., Haas J., Chong T.M., Bruckner J.J., Dann G.C., Dong L., et al. Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. J Clin Invest 2012, 122:654-673.
63. Kalantari-Dehaghi M., Chun S., Chentoufi A., Pablo J., Liang L., Dasgupta G., et al. Discovery of potential diagnostic and vaccine antigens in herpes simplex virus-1 and -2 by proteome-wide antibody profiling. J Virol 2012, 86:4328-4339.
64. Dasgupta G., Chentoufi A.A., Kalantari M., Falatoonzadeh P., Chun S., Lim C.H., et al. Immunodominant "Asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals. J Virol 2012, 86:4358-4369.
65. Chentoufi A.A., Binder N.R., Berka N., Durand G., Nguyen A., Bettahi I., et al. Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J Virol 2008, 82:11792-11802.
66. Skoberne M., Cardin R., Lee A., Kazimirova A., Zielinski V., Garvie D., et al. An adjuvanted herpes simplex virus type 2 (HSV-2) subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in guinea pigs. J Virol 2013, 87:3930-3942.
67. Laing K., Magaret A., Mueller D., Zhao L., Johnston C., De Rosa S., et al. Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol 2010, 30:703-722.
68. St.Leger A.J., Peters B., Sidney J., Sette A., Hendricks R.L. Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice. J Immunol 2011, 186:3927-3933.
69. Koelle D.M., Liu Z., McClurkan C.L., Cevallos R.C., Vieira J., Hosken N.A., et al. Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A 2003, 100:12899-12904.
70. Jing L., Schiffer J.T., Chong T.M., Bruckner J.J., Davies D.H., Felgner P.L., et al. CD4 T-cell memory responses to viral infections of humans show pronounced immunodominance independent of duration or viral persistence. J Virol 2013, 87:2617-2627.
71. Koelle D.M., Posavad C.M., Barnum G.R., Johnson M.L., Frank J.M., Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998, 101:1500-1508.
72. Koelle D.M., Liu Z., McClurkan C.M., Topp M.S., Riddell S.R., Pamer E.G., et al. Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest 2002, 110:537-548.
73. Verjans G.M.G.M., Hintzen R.Q., van Dun J.M., Poot A., Milikan J.C., Laman J.D., et al. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A 2007, 104:3496-3501.
74. Verjans G.M., Dings M.E., McLauchlan J., van Der Kooi A., Hoogerhout P., Brugghe H.F., et al. cells of patients with herpes simplex virus (HSV)-induced acute retinal necrosis recognize HSV tegument proteins VP11/12 and VP13/14. J Infect Dis 2000, 182:923-927.
75. Koelle D.M., Schomogyi M., Corey L., Antigen-specific T. cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection. J Infect Dis 2000, 182:662-670.
76. Schiffer J.T., Abu-Raddad L., Mark K.E., Zhu J., Selke S., Magaret A., et al. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med 2009, 1:7-16.
77. Johnston C., Koelle D.M., Wald A. HSV-2: in pursuit of a vaccine. J Clin Invest 2011, 121:4600-4609.
78. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas J.M., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999, 282:331-340.
79. Langenberg A.G., Burke R.L., Adair S.F., Sekulovich R., Tigges M., Dekker C.L., et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann Intern Med 1995, 122:889-898.
80. Bernstein D.I., Aoki F.Y., Tyring S.K., Stanberry L.R., St-Pierre C., Shafran S.D., et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 2005, 40:1271-1281.
81. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347:1652-1661.
82. Belshe R.B., Leone P.A., Bernstein D.I., Wald A., Levin M.J., Stapleton J.T., et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012, 366:34-43.
83. Balachandran N., Oba D.E., Hutt-Fletcher L.M. Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus. J Virol 1987, 61:1125-1135.
84. Straus S.E., Corey L., Burke R.L., Savarese B., Barnum G., Krause P.R., et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994, 343:1460-1463.
85. Straus S.E., Wald A., Kost R.G., McKenzie R., Langenberg A.G., Hohman P., et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997, 176:1129-1134.
86. Casanova G., Cancela R., Alonzo L., Benuto R., Magana Mdel C., Hurley D.R., et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 2002, 70:235-239.
87. de Bruyn G., Vargas-Cortez M., Warren T., Tyring S.K., Fife K.H., Lalezari J., et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006, 24:914-920.
88. Okuku H.S., Sanders E.J., Nyiro J., Ngetsa C., Ohuma E., McClelland R.S., et al. Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1-seronegative Kenyan men and Women reporting high-risk sexual behavior. Sex Transm Dis 2011, 38:837-844. 10.1097/OLQ.0b013e31821a6225.
89. Dudek T.E., Torres-Lopez E., Crumpacker C., Knipe D.M. Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa. J Infect Dis 2011, 203:1434-1441.
90. Garnett G.P., Dubin G., Slaoui M., Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect 2004, 80:24-29.
91. Schwartz E.J., Blower S. Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines. J Infect Dis 2005, 191:1734-1746.
92. Alsallaq R.A., Schiffer J.T., Longini I.M., Wald A., Corey L., Abu-Raddad L.J. Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. Sex Transm Dis 2010, 37:290-297.
93. Johnston C., Saracino M., Kuntz S., Magaret A., Selke S., Huang M-l., et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet 2012, 379:641-647.
94. Tronstein E., Johnston C., Huang M.L., Selke S., Magaret A., Warren T., et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011, 305:1441-1449.
95. Halford W.P., Puschel R., Gershburg E., Wilber A., Gershburg S., Rakowski B. A live-attenuated HSV-2 ICP0(-) virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS ONE 2011, 6:e17748.
96. Luo C., Goshima F., Kamakura M., Mutoh Y., Iwata S., Kimura H., et al. Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant. HF10, protects mice from genital disease caused by herpes simplex virus type 2. Front Microbiol 2012, 3.
97. Wang F., Zumbrun E.E., Huang J., Si H., Makaroun L., Friedman H.M. Herpes simplex virus type 2 glycoprotein E is required for efficient virus spread from epithelial cells to neurons and for targeting viral proteins from the neuron cell body into axons. Virology 2010, 405:269-279.
98. Awasthi S., Zumbrun E.E., Si H., Wang F., Shaw C.E., Cai M., et al. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. J Virol 2012, 86:4586-4598.
99. Prichard M.N., Kaiwar R., Jackman W.T., Quenelle D.C., Collins D.J., Kern E.R., et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 2005, 23:5424-5431.
100. Da Costa X., Kramer M.F., Zhu J., Brockman M.A., Knipe D.M. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 2000, 74:7963-7971.
101. Hoshino Y., Dalai S.K., Wang K., Pesnicak L., Lau T.Y., Knipe D.M., et al. Comparative efficacy and immunogenicity of replication-defective. Recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 2005, 79:410-418.
102. Hoshino Y., Pesnicak L., Dowdell K.C., Burbelo P.D., Knipe D.M., Straus S.E., et al. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 2009, 200:1088-1095.
103. Mundle S.T., Hernandez H., Hamberger J., Catalan J., Zhou C., Stegalkina S., et al. High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo. PLoS ONE 2013, 8:e57224.
104. Akhrameyeva N.V., Zhang P., Sugiyama N., Behar S.M., Yao F. Development of a glycoprotein d-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J Virol 2011, 85:5036-5047.
105. Morello C.S., Levinson M.S., Kraynyak K.A., Spector D.H. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol 2011, 85:3461-3472.
106. Morello C.S., Kraynyak K.A., Levinson M.S., Chen Z., Lee K.-F., Spector D.H. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine 2012, 30:6541-6550.
107. Chiuppesi F., Vannucci L., De Luca A., Lai M., Matteoli B., Freer G., et al. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein b vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J Virol 2012, 86:6563-6574.
108. ®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 2012, 30:7046-7051.
109. Cortesi R., Ravani L., Rinaldi F., Marconi P., Drechsler M., Manservigi M., et al. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes. Int J Pharm 2013, 440:229-237.
110. Tirabassi R.S., Ace C.I., Levchenko T., Torchilin V.P., Selin L.K., Nie S., et al. A mucosal vaccination approach for herpes simplex virus type 2. Vaccine 2011, 29:1090-1098.
111. Kask A.S., Chen X., Marshak J.O., Dong L., Saracino M., Chen D., et al. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine 2010, 28:7483-7491.
112. Wald A., Koelle D.M., Fife K., Warren T., LeClair K., Chicz R.M., et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 2011, 29:8520-8529.
113. Aurelian L., Kokuba H., Smith C.C. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 1999, 17:1951-1963.
114. Thomas S, Barton S, Reay P, Marshall T, Love C, Goldsweig H, et al. Clinical development of an immune evasion gene-deleted live attenuated vaccine for HSV-2 (ImmunoVEX HSV2). International Herpesvirus Workshop. Salt Lake City, UT2010.
115. Dutton J.L., Li B., Woo W.-P., Marshak J.O., Xu Y., Huang M.-L., et al. A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice. PLOS One 2013, in press.